Potential of genetically engineered anti-ganglioside GD2 antibodies for cancer immunotherapy.
Reisfeld
R A
RA
Scripps Research Institute, Department of Immunology, La Jolla, CA.
Mueller
B M
BM
Handgretinger
R
R
Yu
A L
AL
Gillies
S D
SD
D000818:Animals; D000911:Antibodies, Monoclonal / Q000235:genetics* / Q000627:therapeutic use; D005732:Gangliosides / Q000276:immunology*; D005818:Genetic Engineering; D006801:Humans; D009369:Neoplasms / Q000628:therapy*
D000911:Antibodies, Monoclonal; D005732:Gangliosides; C019403:ganglioside, GD2